The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor

J. P. Lawrence, J. Ishizuka, B. Haber, Courtney Townsend, J. C. Thompson

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

One of the major manifestations of the carcinoid syndrome is secretory diarrhea thought to be due to overproduction of 5-hydroxytryptamine (5-HT). Synthetic somatostatin analogues have proved to be clinically effective in controlling this diarrhea. We have established a continuous cell line from a human pancreatic carcinoid tumor that secretes 5-HT. We examined the ability of the somatostatin analogue, SMS 201-995, to inhibit 5-HT release in vitro. Tumor cells were exposed to SMS 201-995 (10-6 mol/L), pentagastrin (10-9 mol/L), acetylcholine (10-5 mol/L), and isoproterenol (10-5 mol/L) alone and in combination; 5-HT release was assayed with high pressure liquid chromatography. We found that pentagastrin (6.43 ± 0.64 ng/ml), isoproterenol (20.24 ± 2.17 ng/ml), and acetylcholine (12.39 ± 1.10 ng/ml) each stimulated release of 5-HT compared to control values (4.38 ± 0.42 ng/ml). SMS 201-995 significantly reduced release of 5-HT in response to isoproterenol and acetylcholine but did not inhibit the effect of pentagastin. These data suggest that different agents do not act through the same pathway to stimulate 5-HT release from human pancreatic carcinoid cells.

Original languageEnglish (US)
Pages (from-to)1131-1135
Number of pages5
JournalSurgery
Volume108
Issue number6
StatePublished - 1990

Fingerprint

Carcinoid Tumor
Somatostatin
Serotonin
Octreotide
Isoproterenol
Acetylcholine
Pentagastrin
Diarrhea
High Pressure Liquid Chromatography
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Lawrence, J. P., Ishizuka, J., Haber, B., Townsend, C., & Thompson, J. C. (1990). The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor. Surgery, 108(6), 1131-1135.

The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor. / Lawrence, J. P.; Ishizuka, J.; Haber, B.; Townsend, Courtney; Thompson, J. C.

In: Surgery, Vol. 108, No. 6, 1990, p. 1131-1135.

Research output: Contribution to journalArticle

Lawrence, JP, Ishizuka, J, Haber, B, Townsend, C & Thompson, JC 1990, 'The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor', Surgery, vol. 108, no. 6, pp. 1131-1135.
Lawrence JP, Ishizuka J, Haber B, Townsend C, Thompson JC. The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor. Surgery. 1990;108(6):1131-1135.
Lawrence, J. P. ; Ishizuka, J. ; Haber, B. ; Townsend, Courtney ; Thompson, J. C. / The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor. In: Surgery. 1990 ; Vol. 108, No. 6. pp. 1131-1135.
@article{7a671701303a401eb96f35fd372c10b3,
title = "The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor",
abstract = "One of the major manifestations of the carcinoid syndrome is secretory diarrhea thought to be due to overproduction of 5-hydroxytryptamine (5-HT). Synthetic somatostatin analogues have proved to be clinically effective in controlling this diarrhea. We have established a continuous cell line from a human pancreatic carcinoid tumor that secretes 5-HT. We examined the ability of the somatostatin analogue, SMS 201-995, to inhibit 5-HT release in vitro. Tumor cells were exposed to SMS 201-995 (10-6 mol/L), pentagastrin (10-9 mol/L), acetylcholine (10-5 mol/L), and isoproterenol (10-5 mol/L) alone and in combination; 5-HT release was assayed with high pressure liquid chromatography. We found that pentagastrin (6.43 ± 0.64 ng/ml), isoproterenol (20.24 ± 2.17 ng/ml), and acetylcholine (12.39 ± 1.10 ng/ml) each stimulated release of 5-HT compared to control values (4.38 ± 0.42 ng/ml). SMS 201-995 significantly reduced release of 5-HT in response to isoproterenol and acetylcholine but did not inhibit the effect of pentagastin. These data suggest that different agents do not act through the same pathway to stimulate 5-HT release from human pancreatic carcinoid cells.",
author = "Lawrence, {J. P.} and J. Ishizuka and B. Haber and Courtney Townsend and Thompson, {J. C.}",
year = "1990",
language = "English (US)",
volume = "108",
pages = "1131--1135",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor

AU - Lawrence, J. P.

AU - Ishizuka, J.

AU - Haber, B.

AU - Townsend, Courtney

AU - Thompson, J. C.

PY - 1990

Y1 - 1990

N2 - One of the major manifestations of the carcinoid syndrome is secretory diarrhea thought to be due to overproduction of 5-hydroxytryptamine (5-HT). Synthetic somatostatin analogues have proved to be clinically effective in controlling this diarrhea. We have established a continuous cell line from a human pancreatic carcinoid tumor that secretes 5-HT. We examined the ability of the somatostatin analogue, SMS 201-995, to inhibit 5-HT release in vitro. Tumor cells were exposed to SMS 201-995 (10-6 mol/L), pentagastrin (10-9 mol/L), acetylcholine (10-5 mol/L), and isoproterenol (10-5 mol/L) alone and in combination; 5-HT release was assayed with high pressure liquid chromatography. We found that pentagastrin (6.43 ± 0.64 ng/ml), isoproterenol (20.24 ± 2.17 ng/ml), and acetylcholine (12.39 ± 1.10 ng/ml) each stimulated release of 5-HT compared to control values (4.38 ± 0.42 ng/ml). SMS 201-995 significantly reduced release of 5-HT in response to isoproterenol and acetylcholine but did not inhibit the effect of pentagastin. These data suggest that different agents do not act through the same pathway to stimulate 5-HT release from human pancreatic carcinoid cells.

AB - One of the major manifestations of the carcinoid syndrome is secretory diarrhea thought to be due to overproduction of 5-hydroxytryptamine (5-HT). Synthetic somatostatin analogues have proved to be clinically effective in controlling this diarrhea. We have established a continuous cell line from a human pancreatic carcinoid tumor that secretes 5-HT. We examined the ability of the somatostatin analogue, SMS 201-995, to inhibit 5-HT release in vitro. Tumor cells were exposed to SMS 201-995 (10-6 mol/L), pentagastrin (10-9 mol/L), acetylcholine (10-5 mol/L), and isoproterenol (10-5 mol/L) alone and in combination; 5-HT release was assayed with high pressure liquid chromatography. We found that pentagastrin (6.43 ± 0.64 ng/ml), isoproterenol (20.24 ± 2.17 ng/ml), and acetylcholine (12.39 ± 1.10 ng/ml) each stimulated release of 5-HT compared to control values (4.38 ± 0.42 ng/ml). SMS 201-995 significantly reduced release of 5-HT in response to isoproterenol and acetylcholine but did not inhibit the effect of pentagastin. These data suggest that different agents do not act through the same pathway to stimulate 5-HT release from human pancreatic carcinoid cells.

UR - http://www.scopus.com/inward/record.url?scp=0025667244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025667244&partnerID=8YFLogxK

M3 - Article

C2 - 1978946

AN - SCOPUS:0025667244

VL - 108

SP - 1131

EP - 1135

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 6

ER -